Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma

European Journal of Haematology

Volumn 91, Issue 2, 2013, Pages 122-128

  Głowala Kosińska, Magdalena ^a   Chwieduk, Agata ^a   Nieckula, Jarosław ^a   Saduś Wojciechowska, Maria ^a   Grosicki, Sebastian ^b   Rusin, Aleksandra ^a   Nowara, Elzbieta ^a   Giebel, Sebastian ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Division of Surgery   (Poland)

Author keywords

Diffuse large B cell lymphoma; Prognosis; Regulatory T cells; Treg

Indexed keywords

CD39 ANTIGEN; CD45RA ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; L SELECTIN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGRESSION; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MALE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

DIFFUSE LARGE B-CELL LYMPHOMA; PROGNOSIS; REGULATORY T CELLS; TREG;

ADULT; AGED; ANTIGENS, CD; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INCIDENCE; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84880315377     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12144     Document Type: Article

References (19)

1. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-67.
2. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010;10:1573-86.
3. Kelley TW, Parker CJ. CD4(+) CD25(+) Foxp3(+) regulatory T cells and hematologic malignancies. Front Biosci 2010;2:980-92.
4. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clil Oncol 2007;25:579-86.
5. Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 2007;56:271-85.
6. Liu L, Yao JX, Ding Q, Huang SA. [CD4+ CD25high regulatory T cells in peripheral blood of patients with B cell non-Hodgkin's lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:119-22.
7. Lin H, Sun XF, Zhen ZJ, Xia Y, Ling JY, Huang HQ, Xia ZJ, Lin TY. [Correlation between peripheral blood CD4+ CD25high CD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin's lymphoma]. Ai Zheng 2009;28:1186-92.
8. Bosler DS, Douglas-Nikitin VK, Harris VN, Smith MD. Detection of T-regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma. Cytometry B Clin Cytom 2008;74:227-35.
9. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4+ CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-70.
10. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64.
11. Lindqvist CA, Loskog AS. T regulatory cells in B-cell malignancy - tumour support or kiss of death? Immunology 2012;135:255-60.
12. Lindqvist CA, Christiansson LH, Thörn I, et al. Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology 2011;133:296-306.
13. Koreishi AF, Saenz AJ, Persky DO, Cui H, Moskowitz A, Moskowitz CH, Teruya-Feldstein J. The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2010;18:206-11.
14. Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010;16:637-50.
15. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
16. Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, Lee JH, Yim CY, Kwak JY. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247-56.
17. Dehghani M, Sharifpour S, Amirghofran Z, Zare HR. Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients. Med Oncol 2012;29:2364-71.
18. Saez AI, García-Cosío M, Sáez AJ, et al. Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2009;50:571-81.
19. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007;137:364-73.